Equity Profile

AXSM

Axsome Therapeutics, Inc.

Health CarePharmaceuticals$11.2B

Aug3Mon

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Axsome Therapeutics, Inc. is a pharmaceutical company focused on developing innovative therapies for central nervous system disorders....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well the company is managing its expenses relative to its revenue.

$-0.84

Revenue

Revenue figures will provide insight into the company's sales performance and market demand for its products.

$222M

Wall Street expectations, options signals, track record, and call prep available with Pro.

AXSM Q2-2026 Earnings Preview

Context

Company Snapshot

Axsome Therapeutics, Inc. is a pharmaceutical company focused on developing innovative therapies for central nervous system disorders. With a market cap of $11 billion, its work is significant in a sector that is increasingly prioritizing mental health and neurological treatments.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

-16.02%

Avg Stock Reaction

+2.10%

Last Quarter Recap

In Q1-2026, Axsome reported an EPS of $-1.26, which was a significant miss compared to the estimate of $-0.85. The stock reacted positively, gaining 8.31% the following day despite the earnings miss.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts are expecting a challenging quarter with a consensus EPS of $-0.84 and revenue of $222 million. The market will be closely watching for any signs of improvement in financial performance.

Bull Case

If Axsome can beat the EPS estimate and show strong revenue growth, it could signal a turnaround in its financial health, leading to increased investor confidence.

Bear Case

Conversely, if the company fails to meet expectations again, it could raise concerns about its product pipeline and overall viability, leading to a potential decline in stock price.

Key Metrics to Watch

EPS

$-0.84

Earnings per share is a key indicator of profitability and will show how well the company is managing its expenses relative to its revenue.

Revenue

$222M

Revenue figures will provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Axsome's revenue exceed the consensus estimate of $222 million?

Surpassing this revenue target could indicate strong demand for its products and a positive market response.

What specific steps is management taking to improve EPS from the expected $-0.84?

Investors will want to hear concrete plans to address profitability, especially after recent misses.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Axsome to surprise on revenue due to recent positive trends in CNS disorder treatments.

Supporting Evidence

The stock has shown resilience with positive reactions even after earnings misses, indicating underlying investor confidence.

Options pricing suggests a significant move, which could reflect expectations for a surprise in either direction.

Key Risk

If revenue comes in significantly higher than $222 million, it could challenge current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around Axsome's ability to improve its earnings and revenue amidst ongoing challenges.

Bull Confirmed If

An EPS of $-0.50 or better would confirm the bull case, indicating improved cost management and sales.

Bear Confirmed If

An EPS worse than $-1.00 would confirm the bear case, raising concerns about the company's financial health.

Pre-Earnings Positioning

Options Market

Implied Move

±19.2%

Historical Avg

±4.3%

Pricing rich

The options market is pricing in a significant potential movement in the stock price, indicating uncertainty about the upcoming earnings report.

Options are pricing ±19.2% while AXSM has averaged ±4.3% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

48.8%

Calls (91K)P/C Ratio: 0.88Puts (5K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Axsome beats expectations, history suggests a potential stock increase of around +2.93%, confirming a positive shift in financial performance.

In-Line / Cautious

If results are in line with expectations, the stock may see a muted reaction as investors await further clarity on future growth.

Miss

Should the company miss expectations, history indicates a potential decline of around +1.28%, raising concerns about its product pipeline.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the sales performance of Axsome's key products.
2Management's commentary on cost-cutting measures and their impact on EPS.
3Insights into the company's pipeline and any upcoming product launches.
4Discussion of market conditions affecting CNS treatments.
5Any changes in guidance or outlook for the remainder of the year.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jul31

SONYBMO

Sony Group Corporation

PreviewView

Jul31

ENBBMO

Company Snapshot

Axsome Therapeutics, Inc. is a pharmaceutical company focused on developing innovative therapies for central nervous system disorders....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well the company is managing its expenses relative to its revenue.

$-0.84

Revenue

Revenue figures will provide insight into the company's sales performance and market demand for its products.

$222M

Wall Street expectations, options signals, track record, and call prep available with Pro.

AXSM Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

-16.02%

Avg Stock Reaction

+2.10%

Last Quarter Recap

In Q1-2026, Axsome reported an EPS of $-1.26, which was a significant miss compared to the estimate of $-0.85. The stock reacted positively, gaining 8.31% the following day despite the earnings miss.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts are expecting a challenging quarter with a consensus EPS of $-0.84 and revenue of $222 million. The market will be closely watching for any signs of improvement in financial performance.

Bull Case

If Axsome can beat the EPS estimate and show strong revenue growth, it could signal a turnaround in its financial health, leading to increased investor confidence.

Bear Case

Conversely, if the company fails to meet expectations again, it could raise concerns about its product pipeline and overall viability, leading to a potential decline in stock price.

Key Metrics to Watch

EPS

$-0.84

Earnings per share is a key indicator of profitability and will show how well the company is managing its expenses relative to its revenue.

Revenue

$222M

Revenue figures will provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Axsome's revenue exceed the consensus estimate of $222 million?

Surpassing this revenue target could indicate strong demand for its products and a positive market response.

What specific steps is management taking to improve EPS from the expected $-0.84?

Investors will want to hear concrete plans to address profitability, especially after recent misses.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Axsome to surprise on revenue due to recent positive trends in CNS disorder treatments.

Supporting Evidence

The stock has shown resilience with positive reactions even after earnings misses, indicating underlying investor confidence.

Options pricing suggests a significant move, which could reflect expectations for a surprise in either direction.

Key Risk

If revenue comes in significantly higher than $222 million, it could challenge current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around Axsome's ability to improve its earnings and revenue amidst ongoing challenges.

Bull Confirmed If

An EPS of $-0.50 or better would confirm the bull case, indicating improved cost management and sales.

Bear Confirmed If

An EPS worse than $-1.00 would confirm the bear case, raising concerns about the company's financial health.

Pre-Earnings Positioning

Options Market

Implied Move

±19.2%

Historical Avg

±4.3%

Pricing rich

The options market is pricing in a significant potential movement in the stock price, indicating uncertainty about the upcoming earnings report.

Options are pricing ±19.2% while AXSM has averaged ±4.3% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

48.8%

Calls (91K)P/C Ratio: 0.88Puts (5K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Axsome beats expectations, history suggests a potential stock increase of around +2.93%, confirming a positive shift in financial performance.

In-Line / Cautious

If results are in line with expectations, the stock may see a muted reaction as investors await further clarity on future growth.

Miss

Should the company miss expectations, history indicates a potential decline of around +1.28%, raising concerns about its product pipeline.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the sales performance of Axsome's key products.
2Management's commentary on cost-cutting measures and their impact on EPS.
3Insights into the company's pipeline and any upcoming product launches.
4Discussion of market conditions affecting CNS treatments.
5Any changes in guidance or outlook for the remainder of the year.